Related Experiment Video
Updated: May 10, 2026
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
1,5- diaryl pyrazole-loaded chitosan nanoparticles as COX-2 inhibitors, mitigate neoplastic growth by regulating
Raghul Murugan1, Madesh Selvam2, B Haridevamuthu2
1Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 600077, Tamil Nadu, India.
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) have been researched for their capacity to reduce cancer incidence, primarily due to their COX-2 inhibition properties. However, concerns have arisen regarding the precision of their targeting abilities. Nanoparticle approaches are revolutionizing cancer treatment by enabling targeted drug delivery, which enhances the efficacy and reduces the toxicity of chemotherapy. Particularly, chitosan-based nanoparticles are noteworthy for their biocompatibility, biodegradability, and ability to improve drug delivery. In this study, we synthesized folic acid-conjugated, 1,5-diaryl pyrazole-loaded chitosan (FA-CS-DP) nanoparticles using the ionic gelation method. The bioavailability and anti-neoplastic effects in a 7,12-dimethylbenzanthracene (DMBA)-exposed zebrafish model was investigated. MTT assay showed dose-dependent cytotoxicity of FA-CS-DP nanoparticles against MCF-7 breast cancer. The nanoparticles showed no toxicity to zebrafish embryos up to 100 μg/mL. The nanoparticle reduced oxidative stress and enhanced apoptosis in zebrafish exposed to DMBA. The morphological examination suggests that tumor growth was prevented in the zebrafish's surface and internal regions. The gene expression analysis confirmed the decrease in the expression of anti-inflammatory genes, such as cox-2 and nf-κb, and apoptosis inhibitor genes, such as bcl-2 and mdm2. By regulating the anti-inflammatory and apoptosis inhibitor genes, FA-CS-DP nanoparticle prevents neoplastic growth in the zebrafish model.
Insights
Folic acid-conjugated chitosan nanoparticles effectively reduced cancer growth in zebrafish by targeting inflammation and promoting apoptosis. This novel nanoparticle formulation shows promise for cancer treatment with minimal toxicity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Research
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) show potential in cancer prevention via COX-2 inhibition but lack precise targeting.
- Nanoparticle drug delivery systems offer enhanced efficacy and reduced toxicity in cancer chemotherapy.
- Chitosan-based nanoparticles are biocompatible and biodegradable, ideal for drug delivery applications.
Purpose of the Study:
- To synthesize and evaluate folic acid-conjugated, 1,5-diaryl pyrazole-loaded chitosan (FA-CS-DP) nanoparticles.
- To investigate the anti-neoplastic effects and bioavailability of FA-CS-DP nanoparticles in a zebrafish cancer model.
- To assess the safety and mechanism of action of FA-CS-DP nanoparticles in reducing tumor growth.
Main Methods:
- Synthesis of FA-CS-DP nanoparticles via ionic gelation.
- In vitro cytotoxicity assessment using MTT assay on MCF-7 breast cancer cells.
- In vivo evaluation in a 7,12-dimethylbenzanthracene (DMBA)-induced zebrafish model, including toxicity, oxidative stress, apoptosis, and gene expression analysis.
Main Results:
- FA-CS-DP nanoparticles exhibited dose-dependent cytotoxicity against breast cancer cells.
- No toxicity was observed in zebrafish embryos at concentrations up to 100 μg/mL.
- Nanoparticles reduced oxidative stress, enhanced apoptosis, and inhibited tumor growth in zebrafish, confirmed by decreased expression of cox-2, nf-κb, bcl-2, and mdm2 genes.
Conclusions:
- FA-CS-DP nanoparticles demonstrate significant anti-neoplastic effects in a zebrafish model.
- The mechanism involves the regulation of inflammatory and apoptosis-related genes.
- This targeted nanoparticle approach offers a promising strategy for cancer therapy with improved safety and efficacy.
